Clinical and functional analyses of NUP98-rearranged AML reveal quiescence-associated cell states and IL3RA activation
This study characterizes the clinical heterogeneity and distinct quiescent cell states of NUP98-rearranged AML, identifying that NUP98 fusions, particularly NUP98::NSD1, drive poor outcomes and confer drug resistance through the epigenetic activation of IL3RA/CD123.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Acute myeloid leukemia is a cancer of the blood and bone marrow, a place where the body normally builds new blood cells to keep us alive. In this disease, the machinery that tells cells when to grow and when to stop goes wrong, causing a flood of immature, non-functional cells that crowd out healthy ones. While doctors can often identify the general type of leukemia, the specific genetic errors driving the disease vary wildly from patient to patient. Some of these errors are common and well understood, but others are rare and mysterious. Among these rare culprits is a specific type of genetic mix-up involving a protein called NUP98. When this protein fuses with a partner gene, it creates a hybrid molecule that hijacks the cell's control center, forcing it into a dangerous state. Because these cases are uncommon and the genetic changes are often too small to see with standard microscopes, doctors have struggled to understand exactly how these cells behave or why they are so difficult to treat.
A team of researchers at Hokkaido University set out to solve this puzzle by looking at a large group of patients and building custom models in the laboratory. They gathered data on nearly 1,400 patients with acute myeloid leukemia and found nineteen who carried these specific NUP98 genetic rearrangements. By studying these patients alongside cells they engineered to carry the same genetic errors, the scientists discovered that these cancer cells are not just growing out of control; they are actually hiding. The fusion proteins force the cells into a dormant, resting state where they stop dividing. This might sound like a good thing, but in the context of cancer, it is a survival tactic. Because most chemotherapy drugs are designed to kill cells that are actively dividing, these resting cells slip through the treatment net, surviving to cause the disease to return. The researchers found that this "hiding" behavior is particularly strong in one specific subtype of the disease, where the NUP98 protein fuses with a partner called NSD1. Patients with this specific combination had the shortest time before their disease returned or worsened, and they were less likely to achieve a complete remission compared to those with other NUP98 variations.
To understand how these cells manage to hide and resist drugs, the scientists created a switch in the lab. They took human blood cancer cells and inserted the genetic instructions for the NUP98 fusion proteins, but they added a safety mechanism that allowed them to turn these instructions on and off with a simple chemical trigger. When they flipped the switch to turn on the fusion protein, the cells immediately slowed down their growth and piled up in that resting phase. This confirmed that the genetic error itself was the direct cause of the dormancy. The team then tested how these cells reacted to standard leukemia medicines. The results were stark: when the NUP98::NSD1 fusion was active, the cells became significantly harder to kill with a wide range of drugs, including common chemotherapy agents and newer targeted therapies. This provided a biological explanation for the poor outcomes seen in the patient group, showing that the cancer cells were fundamentally changing their nature to survive the assault.
The researchers then looked inside the cells to see what genes were being turned on or off. They found that while all NUP98 fusions activated a shared set of genes related to cell development, each specific fusion also had its own unique signature. One of the most important findings was that the NUP98 fusions, particularly the NSD1 version, switched on a gene called IL3RA. This gene produces a receptor on the surface of the cell known as CD123. In healthy blood cells, this receptor is usually quiet, but in these leukemia cells, it was turned up to high volume. The scientists discovered that the fusion protein did not bind directly to the gene to turn it on. Instead, it changed the chemical packaging of the DNA, making the area more open and accessible, which allowed other cellular machinery to flood in and crank up the production of CD123. This high level of CD123 is significant because it marks the cells as potential targets for new types of immunotherapy, which are designed to hunt down cells displaying this specific flag.
The study also explored whether the cells could be tricked into dying by targeting the very machinery that helps the fusion protein work. The researchers tested a compound that inhibits a specific enzyme called EP300, which the fusion proteins rely on to function. When they applied this inhibitor to the cells carrying the NUP98 fusion, the cells became much more sensitive to the treatment and died at higher rates than cells without the fusion. This suggests that while the cancer cells have developed a way to hide from standard drugs, they have become dependent on specific internal pathways that could be blocked. The findings paint a clear picture of a high-risk leukemia subtype that uses dormancy and surface markers to evade treatment, but also reveal specific weaknesses that could be exploited. By identifying that these cells rely on CD123 and specific epigenetic helpers, the researchers have provided a roadmap for developing therapies that might finally catch these elusive cells, offering hope for patients who currently have very few options.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.